Prepping for PhIII cancer study, Sellas reverse merges its way to a public listing
With its one and only cancer drug poised to start a Phase III study sometime later this year, Sellas is getting into the public market game by executing a reverse merger with a post-implosion Galena $GALE.
Just a few weeks ago Galena admitted what quite a few investors had long expected. Its cancer vaccine NeuVax was failing to help breast cancer victims and researchers had to wrap up early, leaving the biotech struggling with a penny stock that had already been pumped up last fall in a 1-for-20 split.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters